220913-32-6
Chemical Structure
Silatecan
Synonym(s): AR-67; DB 67
- CAS No.: 220913-32-6
- Formula:C26H30N2O5Si
- Molecular Weight:478.61
IUPAC Name: (S)-11-(tert-butyldimethylsilyl)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione
InChIKey: XUSKJHCMMWAAHV-SANMLTNESA-N
SMILES: O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C([Si](C)(C(C)(C)C)C)C5=CC(O)=CC=C5N=C4C3=C2)=O
Biological Activity: Silatecan (AR-67) is a blood-brain barrier-permeable derivative of Camptothecin (HY-16560), DNA topoisomerase I inhibitor, an anticancer agent, and a radiosensitizer. Silatecan potently radiosensitizes wild-type p53 gliomas. Silatecan can be used in research related to glioma, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer, breast cancer, cervical cancer, gastric cancer, nasopharyngeal cancer, and uterine cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Silatecan | 96.62% | Silatecan (AR-67) is a blood-brain barrier-permeable derivative of Camptothecin (HY-16560), DNA topoisomerase I inhibitor, an anticancer agent, and a radiosensitizer. Silatecan potently radiosensitizes wild-type p53 gliomas. Silatecan can be used in research related to glioma, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer, breast cancer, cervical cancer, gastric cancer, nasopharyngeal cancer, and uterine cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bom D, et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release. 2001;74(1-3):325-333. [Content Brief]
- [2]. Yeh TK, et al. Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91. Pharmacol Res. 2010;61(2):108-115. [Content Brief]
- [3]. Chen AY, et al. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer. Mol Cancer Ther. 2005;4(2):317-324. [Content Brief]
Keywords
